Home > > > > > Report Detail

Low Back Pain - Pipeline Review, H2 2019

Publisher Name :
Date: 16-Dec-2019
No. of pages: 140
Inquire Before Buying

Low Back Pain - Pipeline Review, H2 2019

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Low Back Pain - Pipeline Review, H2 2019, provides an overview of the Low Back Pain (Central Nervous System) pipeline landscape.

Low back pain can happen anywhere below the ribs and above the legs. Causes of low back pain include overuse, strain, or injury, aging, arthritis, illness and cancer involving the spine. Symptoms include tingling or burning sensation, a dull achy feeling, or sharp pain and weakness in legs or feet. Treatment includes pain medications such NSAIDs (non-steroidal anti-inflammatory drugs) or opioids and muscle relaxants.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Low Back Pain - Pipeline Review, H2 2019, provides comprehensive information on the therapeutics under development for Low Back Pain (Central Nervous System), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Low Back Pain (Central Nervous System) pipeline guide also reviews of key players involved in therapeutic development for Low Back Pain and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, Preclinical and Discovery stages are 1, 5, 14, 6, 4 and 1 respectively.

Low Back Pain (Central Nervous System) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The pipeline guide provides a snapshot of the global therapeutic landscape of Low Back Pain (Central Nervous System).

- The pipeline guide reviews pipeline therapeutics for Low Back Pain (Central Nervous System) by companies and universities/research institutes based on information derived from company and industry-specific sources.

- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.

- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.

- The pipeline guide reviews key companies involved in Low Back Pain (Central Nervous System) therapeutics and enlists all their major and minor projects.

- The pipeline guide evaluates Low Back Pain (Central Nervous System) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.

- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.

- The pipeline guide reviews latest news related to pipeline therapeutics for Low Back Pain (Central Nervous System)

Reasons to buy

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.

- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.

- Find and recognize significant and varied types of therapeutics under development for Low Back Pain (Central Nervous System).

- Classify potential new clients or partners in the target demographic.

- Develop tactical initiatives by understanding the focus areas of leading companies.

- Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.

- Formulate corrective measures for pipeline projects by understanding Low Back Pain (Central Nervous System) pipeline depth and focus of Indication therapeutics.

- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.

- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Low Back Pain - Pipeline Review, H2 2019

Table of Contents
List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Low Back Pain - Overview
Low Back Pain - Therapeutics Development
Pipeline Overview
Pipeline by Companies
Products under Development by Companies
Low Back Pain - Therapeutics Assessment
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Low Back Pain - Companies Involved in Therapeutics Development
Ache Laboratorios Farmaceuticos SA
Adynxx Inc
Allodynic Therapeutics LLC
AnGes Inc
Axsome Therapeutics Inc
BioRestorative Therapies Inc
Bol Pharma
Camurus AB
Daewon Pharmaceutical Co Ltd
Frontier Biotechnologies Inc
Gador SA
Grunenthal GmbH
Hisamitsu Pharmaceutical Co Inc
Imbrium Therapeutics LP
Immune Pharmaceuticals Inc
Inspyr Therapeutics Inc
Intec Pharma Ltd
MD Biosciences GmbH
Mesoblast Ltd
Navipharm Co Ltd
Nektar Therapeutics
Pacira BioSciences Inc
Pfizer Inc
Qingdao Chia Tai Haier Pharmaceutical Co Ltd
Scilex Holding Co
Stayble Therapeutics AB
Sun Pharma Advanced Research Company Ltd
Therapix Biosciences Ltd
WEX Pharmaceuticals Inc
Low Back Pain - Drug Profiles
(aceclofenac + eperisone SR) - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
(acetaminophen + caffeine + diclofenac sodium + orphenadrine) - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
(clonidine + naltrexone) - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
(eperisone + pelubiprofen) - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
(pregabalin PR + etoricoxib) - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
AB-001 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
AK-1830 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
AMG-0101 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
AYX-2 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
BOLDPo-04 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
BRTX-100 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
bupivacaine ER - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
buprenorphine PR - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
cebranopadol - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
cyclobenzaprine hydrochloride SR - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
dronabinol - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
dronabinol + palmidrol - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
HP-3150 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
IG-8801 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
IMB-9011010 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
lidocaine hydrochloride - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
lidocaine hydrochloride - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
MD-22 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
MPC-06ID - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
oxycodegol phosphate - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecule to Agonize ADORA2A for Arthritis Pain, Inflammation and Low Back Pain - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
STA-001 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
STA-363 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
tanezumab - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Tetrodotoxin - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
zoledronate disodium - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Low Back Pain - Dormant Projects
Low Back Pain - Discontinued Products
Low Back Pain - Product Development Milestones
Featured News & Press Releases
Jul 25, 2019: Nektar Therapeutics recieves General Advice letter from the U.S. FDA for NKTR-181
Sep 18, 2018: Camurus announces positive topline phase 3 results for CAM2038 in opioid experienced patients with chronic low-back pain
Jun 14, 2018: New Data for NKTR-181, a First-in-Class Investigational Opioid to Treat Chronic Low Back Pain in Adult Patients New to Opioid Therapy, Presented at College on Problems of Drug Dependence 80th Annual Scientific Meeting
Jun 13, 2018: Analgesic Solutions Presents Data from the Implementation of its Misuse, Abuse, and Diversion Drug Event Reporting System (MADDERS)
May 31, 2018: Nektar Therapeutics Announces Submission of a New Drug Application to the U.S. FDA for NKTR-181, a First-in-Class Investigational Opioid to Treat Chronic Low Back Pain in Adult Patients New to Opioid Therapy
Mar 29, 2018: Mesoblast Phase 3 Cell Therapy Trial for Chronic Low Back Pain Completes Enrollment
Mar 20, 2018: Therapix Biosciences Announces FDA Clearance of Investigational New Drug (IND) for Phase IIa Clinical Trial of THX-110 in the Treatment of Chronic Low Back Pain
Feb 27, 2018: AnGes Announces First Patient Treated with NF-kappa B Decoy in Phase Ib Study to Treat Discogenic Low Back Pain
Sep 25, 2017: Mesoblast Provides Update on lead product candidate MPC-06-ID at Global Healthcare Conferences
Jun 13, 2017: Pfizer and Lilly Receive FDA Fast Track Designation for Tanezumab
Apr 25, 2017: AnGes Announces FDA Clearance of Investigational New Drug Application for NF-kappaB decoy oligo DNA to treat discogenic lower back pain
Mar 24, 2017: AnGes: Investigational New Drug (IND) Application Submitted to the FDA
Mar 20, 2017: NKTR-181 Meets Primary and Secondary Endpoints in Phase 3 SUMMIT-07 Study in Chronic Pain
Mar 15, 2017: Durable Three-Year Outcomes In Degenerative Disc Disease After a Single Injection of Mesoblast's Cell Therapy
Jan 09, 2017: BioRestorative Therapies Submits IND Application to FDA to Treat Patients with Degenerative Disc Disease
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

List of Tables
Number of Products under Development for Low Back Pain, H2 2019
Number of Products under Development by Companies, H2 2019
Number of Products under Development by Companies, H2 2019 (Contd..1), H2 2019
Products under Development by Companies, H2 2019
Products under Development by Companies, H2 2019 (Contd..1), H2 2019
Number of Products by Stage and Target, H2 2019
Number of Products by Stage and Target, H2 2019 (Contd..1), H2 2019
Number of Products by Stage and Mechanism of Action, H2 2019
Number of Products by Stage and Mechanism of Action, H2 2019 (Contd..1), H2 2019
Number of Products by Stage and Route of Administration, H2 2019
Number of Products by Stage and Molecule Type, H2 2019
Low Back Pain - Pipeline by Ache Laboratorios Farmaceuticos SA, H2 2019
Low Back Pain - Pipeline by Adynxx Inc, H2 2019
Low Back Pain - Pipeline by Allodynic Therapeutics LLC, H2 2019
Low Back Pain - Pipeline by AnGes Inc, H2 2019
Low Back Pain - Pipeline by Axsome Therapeutics Inc, H2 2019
Low Back Pain - Pipeline by BioRestorative Therapies Inc, H2 2019
Low Back Pain - Pipeline by Bol Pharma, H2 2019
Low Back Pain - Pipeline by Camurus AB, H2 2019
Low Back Pain - Pipeline by Daewon Pharmaceutical Co Ltd, H2 2019
Low Back Pain - Pipeline by Frontier Biotechnologies Inc, H2 2019
Low Back Pain - Pipeline by Gador SA, H2 2019
Low Back Pain - Pipeline by Grunenthal GmbH, H2 2019
Low Back Pain - Pipeline by Hisamitsu Pharmaceutical Co Inc, H2 2019
Low Back Pain - Pipeline by Imbrium Therapeutics LP, H2 2019
Low Back Pain - Pipeline by Immune Pharmaceuticals Inc, H2 2019
Low Back Pain - Pipeline by Inspyr Therapeutics Inc, H2 2019
Low Back Pain - Pipeline by Intec Pharma Ltd, H2 2019
Low Back Pain - Pipeline by MD Biosciences GmbH, H2 2019
Low Back Pain - Pipeline by Mesoblast Ltd, H2 2019
Low Back Pain - Pipeline by Navipharm Co Ltd, H2 2019
Low Back Pain - Pipeline by Nektar Therapeutics, H2 2019
Low Back Pain - Pipeline by Pacira BioSciences Inc, H2 2019
Low Back Pain - Pipeline by Pfizer Inc, H2 2019
Low Back Pain - Pipeline by Qingdao Chia Tai Haier Pharmaceutical Co Ltd, H2 2019
Low Back Pain - Pipeline by Scilex Holding Co, H2 2019
Low Back Pain - Pipeline by Stayble Therapeutics AB, H2 2019
Low Back Pain - Pipeline by Sun Pharma Advanced Research Company Ltd, H2 2019
Low Back Pain - Pipeline by Therapix Biosciences Ltd, H2 2019
Low Back Pain - Pipeline by WEX Pharmaceuticals Inc, H2 2019
Low Back Pain - Dormant Projects, H2 2019
Low Back Pain - Dormant Projects, H2 2019 (Contd..1), H2 2019
Low Back Pain - Discontinued Products, H2 2019

List of Figures
Number of Products under Development for Low Back Pain, H2 2019
Number of Products under Development by Companies, H2 2019
Number of Products by Top 10 Targets, H2 2019
Number of Products by Stage and Top 10 Targets, H2 2019
Number of Products by Top 10 Mechanism of Actions, H2 2019
Number of Products by Stage and Top 10 Mechanism of Actions, H2 2019
Number of Products by Top 10 Routes of Administration, H2 2019
Number of Products by Stage and Top 10 Routes of Administration, H2 2019
Number of Products by Top 10 Molecule Types, H2 2019
Number of Products by Stage and Top 10 Molecule Types, H2 2019
  • Central Nervous System Disorder Drugs Industry Forecasts - China Focus
    Published: 27-Nov-2023        Price: US 1800 Onwards        Pages: 116
    This study focuses on China's Central Nervous System Disorder Drugs industry forecasts. In the two past decades, the industry has been growing at a fast pace. The dramatic expansions of the manufacturing capabilities and rising consumer consumptions in China have transformed China's society and economy. China is one of the world's major producers for industrial and consumer products. Far outpacing other economies in the world, China is the world's fastest growing market for the consumptions of g......
  • Central Nervous System Disorder Drugs Companies in China
    Published: 27-Nov-2023        Price: US 1800 Onwards        Pages: 48
    This study focuses on China's Central Nervous System Disorder Drugs industry assessments and company profiles. In the two past decades, the industry has been growing at a fast pace. The dramatic expansions of the manufacturing capabilities and rising consumer consumptions in China have transformed China's society and economy. China is one of the world's major producers for industrial and consumer products. Far outpacing other economies in the world, China is the world's fastest growing market fo......
  • Central Nervous System Disorder Drugs Markets in China
    Published: 27-Nov-2023        Price: US 4000 Onwards        Pages: 214
    China's demand for Central Nervous System Disorder Drugs has grown at a fast pace in the past decade. In the next decade, both production and demand will continue to grow. The Chinese economy maintains a high speed growth which has been stimulated by the consecutive increases of industrial output, imports & exports, consumer consumption and capital investment for over two decades. This new study examines China's economic trends, investment environment, industry development, supply and demand, in......
  • Global Drugs of Nervous System Industry Research Report, In-depth Analysis of Current Status and Outlook of Key Countries 2023-2028
    Published: 14-Nov-2023        Price: US 3380 Onwards        Pages: 108
    Market Overview of Global Drugs of Nervous System market: According to our latest research, the global Drugs of Nervous System market looks promising in the next 5 years. As of 2022, the global Drugs of Nervous System market was estimated at USD XX million, and it's anticipated to reach USD XX million in 2028, with a CAGR of XX% during the forecast years. Drugs of Nervous System are drugs used for the treatment of diseases affecting the brain or spinal cord such as epilepsy, ......
  • Central Nervous System Collaboration and Licensing Deals 2016-2023
    Published: 01-Oct-2023        Price: US 3995 Onwards        Pages: 650
    Central Nervous System Collaboration and Licensing Deals provides a comprehensive understanding and unprecedented access to the central nervous system deals entered into by the worlds leading biopharma companies. Fully revised and updated, the report provides details of central nervous system deals from 2016 to 2023. The report provides access to deal payment terms as announced between the parties. This data provides useful insight into the payment and other deal te......
  • Global Drugs of Nervous System Market Insights: Impact of COVID-19 and Future Expectations to 2028
    Published: 24-Feb-2023        Price: US 3260 Onwards        Pages: 123
    Drugs of Nervous System are drugs used for the treatment of diseases affecting the brain or spinal cord such as epilepsy, Parkinson's disease, Alzheimer's disease, depression, anxiety and bipolar disorders. Epilepsy is a chronic brain disorder characterized by recurring seizures. Parkinson's disease is a degenerative CNS disorder associated with symptoms including tremor, rigidity, akinesia and bradykinesia. The Drugs of Nervous System market revenue was XX Million USD in 2022, and will r......
  • Global Drugs of Nervous System Market Research Report 2022 - Market Size, Current Insights and Development Trends
    Published: 26-Jan-2023        Price: US 3450 Onwards        Pages: 111
    Drugs of Nervous System are drugs used for the treatment of diseases affecting the brain or spinal cord such as epilepsy, Parkinson's disease, Alzheimer's disease, depression, anxiety and bipolar disorders. Epilepsy is a chronic brain disorder characterized by recurring seizures. Parkinson's disease is a degenerative CNS disorder associated with symptoms including tremor, rigidity, akinesia and bradykinesia. The report focuses on the Drugs of Nervous System market size, segment si......
  • Encephalopathy Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
    Published: 30-Nov-2022        Price: US 2000 Onwards        Pages: 71
    Encephalopathy Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update Summary Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Encephalopathy - Drugs In Development, 2022, provides an overview of the Encephalopathy (Central Nervous System) pipeline landscape. Encephalopathy is a term for any diffuse disease of the brain that alters brain function or structure. Symptoms include seizures......
  • Metachromatic Leukodystrophy (MLD) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
    Published: 30-Nov-2022        Price: US 2000 Onwards        Pages: 40
    Metachromatic Leukodystrophy (MLD) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update Summary Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Metachromatic Leukodystrophy (MLD) - Drugs In Development, 2022, provides an overview of the Metachromatic Leukodystrophy (MLD) (Central Nervous System) pipeline landscape. Metachromatic leukodystrophy is an inherited disorder characterized ......
    • SERVICES
    Value for Money
    We believe in "optimum utilization of available budget and resources". While servicing our clients' (your) market research requirements, we keep the same approach in focus to help you get the best value for your $$s.
    Ever Growing Inventory
    Ranging from the smallest feasible / required data (datasheets, data facts, SWOT analysis, company profiles, etc) to full research reports that help you make decisions, our inventory is updated almost on a daily basis with the latest industry reports from domain experts that track more than 5000 niche sectors.
    One Stop Solution
    Need a custom research report on medical devices market? Require all available business intelligence on 3D printing industry? Exploring F&B sector of a particular country/region? RnRMarketResearch.com is your one-stop-solution to all market intelligence needs. We not only offer custom research and consulting services, we also "bundle" reports to meet your needs and help you fetch the data analysis you require for your business.
    Dedicated Client Engagement
    Not limited to only "finding" relevant reports for you, our client engagement team dedicates its efforts to understand your "business need" and accordingly maps available research data to help you move forward. Call "your" client engagement executive any time of your day and get your questions answered in order to make the correct business decision.
    Saving Time and Efforts
    Simply share your research requirement details with us and let us do all the hard work to find required intelligence for you. When you add up our "one stop solution" and "dedicated client engagement" services mentioned above, you obviously know the time and effort saving you do by working with us.
    Payment Flexibility
    Working with Fortune 500 organizations, we understand the importance of being flexible for payments. Share your payment terms with us and we will surely match up to them to ensure you get access to required business intelligence data without having to wait for the payment to be done.
    Post-Purchase Research Support
    Have questions after reading a report / datasheet bought through us? Not sure about the methodology used for data available in the research? Talk to us / Share your questions with us and if required, we will connect you with the analyst(s)/author(s) of the report(s) and ensure you get satisfactory answers for the same. Need more data / analysis / report(s) on the topic of your research/project? The RnRMarketResearch.com team is here for you 24X7 to support you with your post-purchase requirements. Subscription Offers & Packages (Get in touch with us for more details - [email protected] / +1 888 391 5441 )
    • Ad Hoc
    • Pay - as - you - go / Bucket Subscriptions
    • Fixed Cost for #of reports
    • Customize / Personalize as per your needs